HER2 Support Group Forums - View Single Post - peptide vaccine prevents her2 tumors in mice, even stopped advanced tumors progressng

Lani · 02-27-2007, 12:48 PM

utilizing his E75 vaccine (already in trials in early bc) WITH herceptin. I have not heard that it has been accepted yet.

Herceptin has been found to decrease T regulatory cells (I don't know to what degree, though)

Decreasing T regulatory cells is not benign, as it can put a person at increased risk for auto-immune diseases, so the question will become one of what risks to accept in which patients.

Since the vaccine seemed also to work with booster injections instead of with agents which decreased T regulatory cells, perhaps that would be tested in a trial long before the other possibility.

It would make sense to test this both in early and in metastatic breast cancer (the latter patients are willing to take more risks of course)

Dr. Knutson is out of Mayo. Will try to check the institutions of the other authors. Their website may have more info. Also--perhaps Dr. Disi of the Univesity of Washington who have an active vaccine program who contributes to this board could let us know from her communication with colleagues and attendance at conferences, if trials of this particular peptide/combination may be
starting soon.

02-27-2007, 12:48 PM	#3
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	Two years ago Dr. Peoples put in a request to start an additional trial utilizing his E75 vaccine (already in trials in early bc) WITH herceptin. I have not heard that it has been accepted yet. Herceptin has been found to decrease T regulatory cells (I don't know to what degree, though) Decreasing T regulatory cells is not benign, as it can put a person at increased risk for auto-immune diseases, so the question will become one of what risks to accept in which patients. Since the vaccine seemed also to work with booster injections instead of with agents which decreased T regulatory cells, perhaps that would be tested in a trial long before the other possibility. It would make sense to test this both in early and in metastatic breast cancer (the latter patients are willing to take more risks of course) Dr. Knutson is out of Mayo. Will try to check the institutions of the other authors. Their website may have more info. Also--perhaps Dr. Disi of the Univesity of Washington who have an active vaccine program who contributes to this board could let us know from her communication with colleagues and attendance at conferences, if trials of this particular peptide/combination may be starting soon.